Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests

Drug treatments from Bristol-Myers Squibb (BMY) and Merck (MRK) designed to battle lung cancer both topped expectations in lung cancer, the companies said Monday, but Bristol shares plunged after Merck's combination proved to be stronger.

X

Both firms tested drugs that harness a patient's immune system to fight cancer. A regimen of Bristol's Opdivo and Yervoy, two immuno-oncology drugs, cut the risk of cancer progression or death by 42% compared with chemotherapy.

Merck's regimen, however,...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Bristol [+]    Myers Squibb [+]    BMY [+]    Merck [+]    MRK [+]    Monday [+]    Opdivo and Yervoy [+]   

More #news: